Enhancing the effectiveness of radioiodine treatment for thyroid cancer
Official title: Improving efficacy of radioiodine treatment of thyroid cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11051244 · Data updated 2026-11-12
This study is looking at how to make radioiodine therapy work better for people with advanced thyroid cancer who haven't had much success with other treatments, by adding special medications that might help the cancer cells absorb the iodine more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $471,416 |
| NIH project number | 5R01CA249663-05 |
| Project ID | NIH-11051244 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced thyroid cancer, particularly those with BRAFV600E mutations who have not responded to standard radioiodine therapy.
✕Less likely to help
Patients with early-stage thyroid cancer or those who respond well to existing radioiodine treatments may not benefit from this research.
What this research studies
This research focuses on improving the effectiveness of radioiodine therapy for patients with advanced thyroid cancer who do not respond well to current treatments. It investigates the role of specific inhibitors that target signaling pathways involved in cancer cell resistance to therapy. By combining these inhibitors with radioiodine treatment, the research aims to enhance the uptake and retention of iodine in cancerous thyroid cells, potentially leading to better treatment outcomes. The study will involve clinical trials to assess the impact of these combined therapies on patients with specific genetic mutations associated with thyroid cancer.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with radioiodine-refractory thyroid cancer.
How similar studies have gone: Previous studies have shown promise in using targeted inhibitors to enhance the effectiveness of cancer therapies, indicating potential for success in this approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Fagin, James a — Sloan-Kettering Inst Can Research
- Study coordinator: Fagin, James a
Related research
Other NIH-funded projects on the same topics.
-
WTC Dust and Thyroid Cancer Progression in Human Organoids
This grant tests how World Trade Center dust might influence thyroid cancer progression using human thyroid organoids to model real-life exposure.
-
Integrating molecular signals to guide thyroid cancer care
A doctor-scientist team at Brigham and Women’s Hospital is studying how tumor biology and the immune environment can guide personalized monitoring and treatment for differentiated thyroid cancer.
-
Metabolic Imaging to Track Treatment Response in Aggressive Thyroid Cancer
This grant explores a new way to watch how aggressive thyroid cancers respond to treatment using a special MRI technique that tracks tumor metabolism.
-
Adoptive T-cell Therapy for Anaplastic Thyroid Cancer
A patient-focused program explores using patient immune cells engineered to target and fight anaplastic thyroid cancer, especially for those whose cancer has stopped responding to standard treatments.
-
Overcoming Resistance to BRAF Inhibitors in Aggressive Thyroid Cancers
A patient-focused research effort to find new ways to treat difficult thyroid cancers that no longer respond to current BRAF inhibitors.
-
Improving Treatment of Anaplastic Thyroid Cancer with New Therapies and Early Response Checks
This NIH grant aims to advance treatment for a rare, aggressive thyroid cancer by testing new approaches and measuring how tumors respond early in treatment to tailor care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.